AI in Bio + Health

Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.

In this episode, Vijay Pande speaks with Jakob Uszkoreit, the cofounder and CEO of Inceptive. Together, they discuss all things AI.

In today’s episode we have two short segments, both on bioscience topics:

On today’s episode, we are making the full arc from the theoretical and borderline philosophical to the applied. Let’s start with the theory: embodied intelligence posits that the body, or the physical form, plays an...

On the path from scientific discovery to new drug, the clinical trial is a huge — and critical — hurdle. Clinical trials are themselves experiments, and to make sure that they are doing the best possible job at deter...

In this episode, we talk with Jeff Hawkins—an entrepreneur and scientist, known for inventing some of the earliest handheld computers, the Palm and the Treo, who then turned his career to neuroscience and founded the R...

There’s been a lot of talk (including on this show!) about the many kinds of innovations and technologies changing healthcare delivery for clinicians and patients. But what’s happening behind the scenes in he...

It seems like investors are especially obsessed with the psychology of decision making — high stakes, after all — but all kinds of decisions, whether in life or business — like dating, product managemen...

a16z Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature — what papers we’re reading, and why they matter from our perspective at the intersection of biology...

Artificial intelligence is coming to the doctor’s office. In this episode, Dr. Eric Topol, cardiologist and chair of innovative medicine at Scripps Research, and a16z’s general partner on the Bio Fund Vijay Pande, ha...

Insights from leaders at OpenAI, Microsoft, Anthropic, Databricks, Character.AI, Roblox, insitro, and Figma on where we are, where we're going, and the open questions for building the next wave of AI.

Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.

We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.

Rick Young is a professor of biology at MIT who studies RNA that is transcribed from the part of the genome that does not code for proteins, known as non-coding DNA. This part of the genome was once referred to as ‘jun...

We’ve come a long way from having to make the case for artificial intelligence (AI) in biology. Just a few years ago, I argued in The New York Times how fears around the “black box” of AI in medicine are often misp...

It’s Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.

Why does the cost of education and healthcare services continue to rise rapidly, while the cost of goods rise much more slowly? According to economics theory, wages rise when there’s greater productivity; but a rise wi...

Bioengineering, once viewed primarily as an academic discipline, is growing up.

The idea of reverse engineering biology seems like a paradox. How could we ever reverse engineer anything for which we didn’t “invent” the original technology? Radios, bridges, computers—all these are human-made,...